IL6 and rheumatoid arthritis: Treatments, including biological disease-modifying anti-rheumatic drugs (DMARDs), such as monoclonal antibodies that target TNF-α and IL-6, and Janus kinase inhibitors, are highly effective in managing RA symptoms in clinical settings [1].